We provide you with 20 years of free, institutional-grade data for RYZB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RYZB. Explore the full financial landscape of RYZB stock.
| Reported Date | CIK | Ticker | Type |
|---|
RayzeBio Inc(NASDAQ:RYZB) 
RayzeBio is a clinical-stage radiopharmaceutical therapeutics (“RPT”) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs.
Website: https://rayzebio.com/
Founded: 2020
CEO: Dr. Kenneth Song
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about RYZB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.